Mr O’Connor has held positions as vice president of sales, business development manager, and North America sales manager for companies such as Luminex.
Mr O’Connor will be based in the US and will be responsible for building SQI’s multiplex immunoassay platform franchise in North America and Europe. SQI intends to file an application with the FDA seeking clearance to market its SQiDworks platform and lead test QuantiSpot RA microarray in the US.
SQiDworks is a fully-automated fluidics workstation, scanner and analytical device used to process SQI Diagnostics proprietary QuantiSpot microarray test devices. The platform fully integrates all assay steps for hands-free work-flow and is said to be compatible with standard lab automation systems.
Claude Ricks, CEO and president of SQI Diagnostics, said: “Thomas’ extensive experience will be a perfect fit for SQI as we move towards the marketing approval and commercialization of SQiDworks platform and QuantiSpot RA microarray consumable test in the US, Canada and Europe.”